No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Evacetrapib is a drug used in the treatment of cardiovascular diseases. It is a cholesteryl ester transfer protein (CETP) inhibitor, which works by blocking the transfer of cholesterol from high-density lipoprotein (HDL) to low-density lipoprotein (LDL). This helps to reduce the risk of cardiovascular events such as heart attack and stroke. Evacetrapib is the first CETP inhibitor to be approved by the US Food and Drug Administration (FDA). It is currently being studied in clinical trials for its potential to reduce the risk of cardiovascular disease.
Evacetrapib is being developed by Eli Lilly and Company, Merck & Co., and Pfizer. Other companies involved in the development of CETP inhibitors include Amgen, AstraZeneca, and Sanofi. Show Less Read more
